These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22711601)

  • 21. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3K-Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy.
    Berdichevsky Y; Dryer AM; Saponjian Y; Mahoney MM; Pimentel CA; Lucini CA; Usenovic M; Staley KJ
    J Neurosci; 2013 May; 33(21):9056-67. PubMed ID: 23699517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
    Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
    Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma.
    Kittipongdaja W; Wu X; Garner J; Liu X; Komas SM; Hwang ST; Schieke SM
    J Invest Dermatol; 2015 Sep; 135(9):2301-2308. PubMed ID: 25897830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
    Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Jolkinolide B inhibits glycolysis by downregulating hexokinase 2 expression through inactivating the Akt/mTOR pathway in non-small cell lung cancer cells.
    Gao X; Han H
    J Cell Biochem; 2018 Jun; 119(6):4967-4974. PubMed ID: 29384225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells.
    Hujber Z; Petővári G; Szoboszlai N; Dankó T; Nagy N; Kriston C; Krencz I; Paku S; Ozohanics O; Drahos L; Jeney A; Sebestyén A
    J Exp Clin Cancer Res; 2017 Jun; 36(1):74. PubMed ID: 28578659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
    Fang G; Zhang P; Liu J; Zhang X; Zhu X; Li R; Wang H
    Cancer Lett; 2019 Oct; 463():11-26. PubMed ID: 31404613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced antitumor activity of 3-bromopyruvate in combination with rapamycin in vivo and in vitro.
    Zhang Q; Pan J; Lubet RA; Komas SM; Kalyanaraman B; Wang Y; You M
    Cancer Prev Res (Phila); 2015 Apr; 8(4):318-26. PubMed ID: 25644152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.
    Peng T; Golub TR; Sabatini DM
    Mol Cell Biol; 2002 Aug; 22(15):5575-84. PubMed ID: 12101249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
    Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
    Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis.
    Gardner TW; Abcouwer SF; Losiewicz MK; Fort PE
    Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E546-56. PubMed ID: 26199279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
    Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
    BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
    Jia L; Huang S; Yin X; Zan Y; Guo Y; Han L
    Life Sci; 2018 Sep; 208():123-130. PubMed ID: 30025823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
    Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
    Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.
    VanderWeele DJ; Zhou R; Rudin CM
    Mol Cancer Ther; 2004 Dec; 3(12):1605-13. PubMed ID: 15634654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.
    Zeng Q; Zhang H; Qin J; Xu Z; Gui L; Liu B; Liu C; Xu C; Liu W; Zhang S; Huang S; Chen L
    Cell Mol Life Sci; 2015 Dec; 72(24):4867-84. PubMed ID: 26118661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.